GALT and galactosemia: The systemic injection in the duct of Cuvier was used in one study to evaluate the effect of LNP-packaged GALT mRNA in a model of classic galactosemia, which resulted in increased enzyme activity and reduced accumulation of metabolites as described in Table 3 [11].